In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
Browsing: type 2 diabetes
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
In patients with uncontrolled type 2 diabetes on metformin, once-weekly semaglutide 1.0 mg and once-daily canagliflozin 300 mg significantly improved…
In patients with type 2 diabetes treated with metformin and basal insulin, once-weekly semaglutide significantly improved glycaemic control (HbA1c reduction)…
In adults with type 2 diabetes inadequately controlled with metformin, semaglutide 1.0 mg once weekly significantly reduced HbA1c and body…
In patients with type 2 diabetes, intensive blood-pressure control (targeting systolic BP <120 mm Hg) significantly reduced cardiovascular events compared to standard treatment (systolic BP <140 mm Hg), though it was associated with increased risks of symptomatic hypotension and hyperkalemia.
In patients with obesity and knee osteoarthritis, once-weekly semaglutide (2.4 mg) significantly reduced body weight and pain compared to placebo, though it was associated with gastrointestinal side effects.
In adults with type 2 diabetes inadequately controlled with metformin (alone or with sulfonylurea), oral semaglutide (7 mg and 14 mg) significantly reduced HbA1c and body weight compared to sitagliptin over 26 weeks, while the 3 mg dose showed no significant benefit.
In patients with inadequately controlled type 2 diabetes on SGLT-2 inhibitors, adding semaglutide significantly improved HbA1c and reduced body weight compared to placebo, though it was associated with an increased frequency of gastrointestinal side effects.
In patients with type 2 diabetes inadequately managed on diet and exercise (with or without metformin), daily subcutaneous semaglutide significantly improved glycaemic control and promoted weight loss compared to both liraglutide and placebo, though it was associated with higher gastrointestinal side effects.